JAMA
Original Investigation
April 6, 2024
Richard M.ÌýMartin,ÌýBM, BS, PhD; Emma L.ÌýTurner,ÌýPhD; Grace J.ÌýYoung,ÌýMSc; ChrisÌýMetcalfe,ÌýPhD; Eleanor I.ÌýWalsh,ÌýMSc; J. AtheneÌýLane,ÌýPhD; Jonathan A. C.ÌýSterne,ÌýPhD; SianÌýNoble,ÌýPhD; PeterÌýHolding,ÌýMSc; YoavÌýBen-Shlomo,ÌýMBBS, PhD; Naomi J.ÌýWilliams,ÌýPhD; NoraÌýPashayan,ÌýMD, PhD; Mai NgocÌýBui,ÌýPhD; Peter C.ÌýAlbertsen,ÌýMD; Tyler M.ÌýSeibert,ÌýMD, PhD; Anthony L.ÌýZietman,ÌýMD; JonÌýOxley,ÌýMD; JanÌýAdolfsson,ÌýMD; Malcolm D.ÌýMason,ÌýMD; GeorgeÌýDavey Smith,ÌýDSc; David E.ÌýNeal,ÌýMD; Freddie C.ÌýHamdy,ÌýMD; Jenny L.ÌýDonovan,ÌýPhD; CAP Trial Group
is active quiz
has multimedia
JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011
This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Oncology
August 8, 2022
E.ÌýLin,ÌýMSc; HansÌýGarmo,ÌýPhD; MiekeÌýVan Hemelrijck,ÌýPhD; BjörnÌýZethelius,ÌýMD, PhD; PärÌýStattin,ÌýMD, PhD; EmilÌýHagström,ÌýMD, PhD; JanÌýAdolfsson,ÌýMD, PhD; DanielleÌýCrawley,ÌýPhD
open access
ÁñÁ«ÊÓƵ Netw Open. 2022; 5(8):e2225600. 10.1001/jamanetworkopen.2022.25600
This cohort study evaluates the association between gonadotropin-releasing hormone agonist use, prostate cancer diagnosis, and cardiovascular (CVD) risk in men with type 2 diabetes.
ÁñÁ«ÊÓƵ Network Open
Original Investigation
Oncology
November 6, 2019
KerriÌýBeckmann,ÌýPhD; DanielleÌýCrawley,ÌýPhD; TobiasÌýNordström,ÌýPhD; MarkusÌýAly,ÌýPhD; HenrikÌýOlsson,ÌýMSc; AnnaÌýLantz,ÌýPhD; NoorÌýBinti Abd Jalal,ÌýMRes; HansÌýGarmo,ÌýPhD; JanÌýAdolfsson,ÌýMD; MartinÌýEklund,ÌýPhD; MiekeÌýVan Hemelrijck,ÌýPhD
open access
ÁñÁ«ÊÓƵ Netw Open. 2019; 2(11):e1914689. 10.1001/jamanetworkopen.2019.14689
This cohort study examines the association between antidiabetic medication and prostate-specific antigen (PSA) levels, frequency of PSA testing and biopsy, and detection of prostate cancer at biopsy among Swedish men with diabetes.